A seismic shift in vaccine policy is underway: The CDC's advisory committee just voted to potentially end the universal hepatitis B shot at birth! What does this mean for your newborn, and why is this decision so controversial?
On December 5, 2025, the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) made a surprising decision. By a vote of 8-3, they recommended removing the long-standing universal recommendation for the hepatitis B vaccine to be administered to all newborns immediately after birth. This isn't a complete removal of the vaccine, but a significant change in how the decision is made.
Instead of a blanket recommendation for all infants, the ACIP now suggests a more individualized approach. The core of the new recommendation hinges on the mother's hepatitis B testing status. If a pregnant woman tests negative for hepatitis B, the decision of whether or not to vaccinate her newborn at birth now rests with the parents, in consultation with their healthcare provider. The ACIP document refers to this as "individual-based decision-making." But here's where it gets controversial... what factors should parents consider?
The new guidelines specify that infants who don't receive the hepatitis B vaccine at birth should receive their first dose no later than two months of age. So, the vaccine is still recommended, just potentially delayed.
And this is the part most people miss: the recommendation remains unchanged for infants born to mothers who test positive for hepatitis B or whose hepatitis B status is unknown. These newborns should still receive the vaccine immediately. This is crucial, as early vaccination is vital to protect them from infection.
The ACIP's document also includes an important footnote. It advises parents and healthcare providers to consider whether the newborn faces specific risk factors. These include having a household member who is hepatitis B-positive or frequent contact with individuals who have emigrated from regions where hepatitis B is prevalent. These factors increase the risk of exposure, making vaccination a more pressing consideration. For example, a family frequently hosting relatives from Southeast Asia, where hepatitis B rates are higher, might lean towards vaccinating their newborn even if the mother tested negative.
In a separate vote, the ACIP also addressed older children. By a vote of 6-4, with one abstention, they recommended that parents discuss hepatitis B antibody testing with their doctor before considering any further hepatitis B vaccinations for their older children. The goal of this testing is to determine if the child has already achieved a sufficient antibody level to protect them from the virus. The recommendation stipulated that such testing should be covered by insurance, removing a potential financial barrier. This could be particularly relevant for children who received a partial vaccine series previously and whose parents are unsure of their immunity status.
The final decision now rests with the CDC acting director, Health and Human Services Deputy Secretary Jim O’Neill, who is expected to sign off on the changes.
This decision raises many questions and potentially sparks differing opinions. Is this a move towards empowering parental choice, or does it risk leaving newborns vulnerable to a serious disease? Does this change disproportionately affect certain communities? What are your thoughts on this shift in policy? Share your perspective in the comments below!
